"President Donald Trump signed a presidential memorandum on Tuesday that calls on federal health agencies to require pharmaceutical companies to disclose more side effects in their ads and enforce existing rules about misleading ads. The administration is pitching the moves as a way to increase transparency for patients. The U.S. is the only place, besides New Zealand, where pharma companies can directly advertise to consumers."
"Drug companies spent $10.8 billion in 2024 on direct-to-consumer pharmaceutical advertising in total, according to a report from the advertising data firm MediaRadar. AbbVie Inc. and Pfizer Inc. were particularly big spenders. AbbVie alone spent $2 billion on direct-to-consumer drug ads last year, primarily on advertising for the company's anti-inflammatory drugs Skyrizi and Rinvoq. The medicines brought in more than $6.5 billion for AbbVie in the second quarter of 2025."
President Donald Trump signed a presidential memorandum directing federal health agencies to require pharmaceutical companies to disclose more side effects in their ads and to enforce existing rules about misleading advertising. The measures aim to increase patient transparency. The U.S. and New Zealand are the only countries allowing direct-to-consumer pharmaceutical advertising. Health and Human Services Secretary Robert F. Kennedy Jr. has prioritized limiting such ads, though the new rules stop short of a ban. The changes are expected to affect pharmaceutical manufacturers and media companies that depend on drug advertising revenue. Drug companies spent $10.8 billion on direct-to-consumer ads in 2024, with AbbVie and Pfizer major spenders. The FDA plans enforcement actions including cease-and-desist and warning letters.
Read at Miami Herald
Unable to calculate read time
Collection
[
|
...
]